{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:15:32Z","timestamp":1789985732828,"version":"4.0.1"},"reference-count":60,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent studies have shown that the transcription factor nuclear factor \u03baB (NF-\u03baB) regulates critical survival pathways in a variety of cancers, including human T-cell leukemia\/lymphotrophic virus 1 (HTLV-1)\u2013transformed CD4 T cells. The activation of NF-\u03baB is controlled by proteasome-mediated degradation of the inhibitor of nuclear factor \u03baB\u03b1 (I\u03baB\u03b1). We investigated the effects of PS-341, a peptide boronate inhibitor of the proteasome in HTLV-1 Tax transgenic tumors in vitro and in vivo. In Tax transgenic mice, PS-341 administered thrice weekly inhibited tumor-associated NF-\u03baB activity. Quantitation of proliferation, apoptosis, and interleukin 6 (IL-6) and IL-10 secretion by tumor cells in culture revealed that the effects of PS-341 on cell growth largely correlated with inhibition of pathways mediated by NF-\u03baB. However, the effect of PS-341 on the growth of tumors in Tax transgenic mice revealed heterogeneity in drug responsiveness. The tumor tissues treated with PS-341 show no consistent inhibition of NF\u03baB activation in vivo. Annexin V staining indicated that PS-341 response in vivo correlated with sensitivity to apoptosis induced by \u03b3 irradiation. On the other hand, transplanted Tax tumors in Rag-1 mice showed consistent inhibition of tumor growth and prolonged survival in response to the same drug regimen. TUNEL staining indicated that PS-341 treatment sensitizes Tax tumors to DNA fragmentation.<\/jats:p>","DOI":"10.1182\/blood-2003-11-3967","type":"journal-article","created":{"date-parts":[[2004,4,20]],"date-time":"2004-04-20T00:16:42Z","timestamp":1082420202000},"page":"802-809","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants"],"prefix":"10.1182","volume":"104","author":[{"given":"Shibani","family":"Mitra-Kaushik","sequence":"first","affiliation":[{"name":"From the Department of Internal Medicine, Washington University School of Medicine, St Louis, MO; and the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Harding","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Washington University School of Medicine, St Louis, MO; and the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay L.","family":"Hess","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Washington University School of Medicine, St Louis, MO; and the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Ratner","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Washington University School of Medicine, St Louis, MO; and the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021220134698900_REF1","doi-asserted-by":"crossref","unstructured":"Bangham CR. HTLV-1 infections. J Clin Pathol.2000;53: 581-586.","DOI":"10.1136\/jcp.53.8.581"},{"key":"2020021220134698900_REF2","doi-asserted-by":"crossref","unstructured":"Edlich RF, Arnette JA, Williams FM. Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I). J Emerg Med.2000;18: 109-119.","DOI":"10.1016\/S0736-4679(99)00173-0"},{"key":"2020021220134698900_REF3","doi-asserted-by":"crossref","unstructured":"Hollsberg P. Pathogenesis of chronic progressive myelopathy associated with human T-cell lymphotropic virus type I. Acta Neurol Scand Suppl.1997;169: 86-93.","DOI":"10.1111\/j.1600-0404.1997.tb08156.x"},{"key":"2020021220134698900_REF4","doi-asserted-by":"crossref","unstructured":"Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol.1997;15: 15-37.","DOI":"10.1146\/annurev.immunol.15.1.15"},{"key":"2020021220134698900_REF5","doi-asserted-by":"crossref","unstructured":"Bazarbachi A, Hermine O. Treatment of adult T-cell leukaemia\/lymphoma: current strategy and future perspectives. Virus Res.2001;78: 79-92.","DOI":"10.1016\/S0168-1702(01)00286-6"},{"key":"2020021220134698900_REF6","doi-asserted-by":"crossref","unstructured":"Siegel RS, Gartenhaus RB, Kuzel TM. Human T-cell lymphotropic-I-associated leukemia\/lymphoma. Curr Treat Options Oncol.2001;2: 291-300.","DOI":"10.1007\/s11864-001-0022-8"},{"key":"2020021220134698900_REF7","doi-asserted-by":"crossref","unstructured":"Giebler HA, Loring JE, van Orden K, et al. Anchoring of CREB binding protein to the human T-cell leukemia virus type 1 promoter: a molecular mechanism of Tax transactivation. Mol Cell Biol.1997;17: 5156-5164.","DOI":"10.1128\/MCB.17.9.5156"},{"key":"2020021220134698900_REF8","doi-asserted-by":"crossref","unstructured":"Xiao G, Cvijic ME, Fong A, et al. Retroviral oncoprotein Tax induces processing of NF-kappaB2\/p100 in T cells: evidence for the involvement of IKKalpha. EMBO J.2001;20: 6805-6815.","DOI":"10.1093\/emboj\/20.23.6805"},{"key":"2020021220134698900_REF9","doi-asserted-by":"crossref","unstructured":"Kikuchi K, Ikeda H, Tsuchikawa T, et al. A novel animal model of thymic tumour: development of epithelial thymoma in transgenic rats carrying human T lymphocyte virus type I pX gene. Int J Exp Pathol.2002;83: 247-255.","DOI":"10.1046\/j.1365-2613.2003.00233.x"},{"key":"2020021220134698900_","doi-asserted-by":"crossref","unstructured":"Habu K, Nakayama-Yamada J, Asano M, et al. The human T cell leukemia virus type I-tax gene is responsible for the development of both inflammatory polyarthropathy resembling rheumatoid arthritis and noninflammatory ankylotic arthropathy in transgenic mice. J Immunol.1999;162: 2956-2963.","DOI":"10.4049\/jimmunol.162.5.2956"},{"key":"2020021220134698900_REF11","doi-asserted-by":"crossref","unstructured":"Grossman WJ, Ratner L. Cytokine expression and tumorigenicity of large granular lymphocytic leukemia cells from mice transgenic for the tax gene of human T-cell leukemia virus type I. Blood. 1997;90: 783-794.","DOI":"10.1182\/blood.V90.2.783"},{"key":"2020021220134698900_REF12","unstructured":"Benvenisty N, Ornitz DM, Bennett GL, et al. Brain tumours and lymphomas in transgenic mice that carry HTLV-I LTR\/c-myc and Ig\/tax genes. Oncogene. 1992;7: 2399-2405."},{"key":"2020021220134698900_REF13","doi-asserted-by":"crossref","unstructured":"Portis T, Harding JC, Ratner L. The contribution of NF-kappa B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. Blood. 2001;98: 1200-1208.","DOI":"10.1182\/blood.V98.4.1200"},{"key":"2020021220134698900_REF14","doi-asserted-by":"crossref","unstructured":"Robek MD, Ratner L. Immortalization of CD4(+) and CD8(+) T lymphocytes by human T-cell leukemia virus type 1 Tax mutants expressed in a functional molecular clone. J Virol.1999;73: 4856-4865.","DOI":"10.1128\/JVI.73.6.4856-4865.1999"},{"key":"2020021220134698900_REF15","doi-asserted-by":"crossref","unstructured":"Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-\u03baB activity. Annu Rev Immunol.2000;18: 621-663.","DOI":"10.1146\/annurev.immunol.18.1.621"},{"key":"2020021220134698900_","doi-asserted-by":"crossref","unstructured":"Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol.1998;16: 225-260.","DOI":"10.1146\/annurev.immunol.16.1.225"},{"key":"2020021220134698900_","unstructured":"Gilmore TD, Koedood M, Piffat KA, White DW. Rel\/NF-kappaB\/IkappaB proteins and cancer. Oncogene. 1996;13: 1367-1378."},{"key":"2020021220134698900_","doi-asserted-by":"crossref","unstructured":"Barkett M, Gilmore TD. Control of apoptosis by Rel\/NF-kappaB transcription factors. Oncogene. 1999;18: 6910-6924.","DOI":"10.1038\/sj.onc.1203238"},{"key":"2020021220134698900_REF19","doi-asserted-by":"crossref","unstructured":"Sha WC. Regulation of immune responses by NF-kappa B\/Rel transcription factor. J Exp Med.1998;187: 143-146.","DOI":"10.1084\/jem.187.2.143"},{"key":"2020021220134698900_REF20","doi-asserted-by":"crossref","unstructured":"Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol.1994;10: 405-455.","DOI":"10.1146\/annurev.cb.10.110194.002201"},{"key":"2020021220134698900_REF21","doi-asserted-by":"crossref","unstructured":"Baldwin AS, Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol.1996;14: 649-683.","DOI":"10.1146\/annurev.immunol.14.1.649"},{"key":"2020021220134698900_REF22","doi-asserted-by":"crossref","unstructured":"Brockman JA, Scherer DC, McKinsey TA, et al. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol.1995;15: 2809-2818.","DOI":"10.1128\/MCB.15.5.2809"},{"key":"2020021220134698900_REF23","doi-asserted-by":"crossref","unstructured":"Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science. 1995;267: 1485-1488.","DOI":"10.1126\/science.7878466"},{"key":"2020021220134698900_REF24","doi-asserted-by":"crossref","unstructured":"Sun SC, Ballard DW. Persistent activation of NF-kappaB by the tax transforming protein of HTLV-1: hijacking cellular IkappaB kinases. Oncogene. 1999;18: 6948-6958.","DOI":"10.1038\/sj.onc.1203220"},{"key":"2020021220134698900_REF25","doi-asserted-by":"crossref","unstructured":"Hiscott J, Kwon H, Genin P. Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Invest.2001;107: 143-151.","DOI":"10.1172\/JCI11918"},{"key":"2020021220134698900_REF26","doi-asserted-by":"crossref","unstructured":"Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol.2000;12: 85-98.","DOI":"10.1006\/smim.2000.0210"},{"key":"2020021220134698900_REF27","doi-asserted-by":"crossref","unstructured":"Fan CM, Maniatis T. Generation of p50 subunit of NF-kappa B by processing of p105 through an ATP-dependent pathway. Nature. 1991;354: 395-398.","DOI":"10.1038\/354395a0"},{"key":"2020021220134698900_REF28","doi-asserted-by":"crossref","unstructured":"Chu ZL, DiDonato JA, Hawiger J, Ballard DW. The tax oncoprotein of human T-cell leukemia virus type 1 associates with and persistently activates IkappaB kinases containing IKKalpha and IKKbeta. J Biol Chem.1998;273: 15891-15894.","DOI":"10.1074\/jbc.273.26.15891"},{"key":"2020021220134698900_REF29","doi-asserted-by":"crossref","unstructured":"Geleziunas R, Ferrell S, Lin X, et al. Human T-cell leukemia virus type 1 Tax induction of NF-kappaB involves activation of the IkappaB kinase alpha (IKKalpha) and IKKbeta cellular kinases. Mol Cell Biol.1998;18: 5157-5165.","DOI":"10.1128\/MCB.18.9.5157"},{"key":"2020021220134698900_","doi-asserted-by":"crossref","unstructured":"Uhlik M, Good L, Xiao G, et al. NF-kappaB-inducing kinase and IkappaB kinase participate in human T-cell leukemia virus I Tax-mediated NF-kappaB activation. J Biol Chem.1998;273: 21132-21136.","DOI":"10.1074\/jbc.273.33.21132"},{"key":"2020021220134698900_REF31","doi-asserted-by":"crossref","unstructured":"Yin MJ, Christerson LB, Yamamoto Y, et al. HTLV-I Tax protein binds to MEKK1 to stimulate IkappaB kinase activity and NF-kappaB activation. Cell. 1998;93: 875-884.","DOI":"10.1016\/S0092-8674(00)81447-6"},{"key":"2020021220134698900_REF32","doi-asserted-by":"crossref","unstructured":"Yamaoka S, Courtois G, Bessia C, et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell. 1998;93: 1231-1240.","DOI":"10.1016\/S0092-8674(00)81466-X"},{"key":"2020021220134698900_REF33","doi-asserted-by":"crossref","unstructured":"Harhaj EW, Good L, Xiao G, et al. Somatic mutagenesis studies of NF-kappa B signaling in human T cells: evidence for an essential role of IKK gamma in NF-kappa B activation by T-cell costimulatory signals and HTLV-I Tax protein. Oncogene. 2000;19: 1448-1456.","DOI":"10.1038\/sj.onc.1203445"},{"key":"2020021220134698900_REF34","doi-asserted-by":"crossref","unstructured":"Harhaj EW, Sun SC. IKKgamma serves as a docking subunit of the IkappaB kinase (IKK) and mediates interaction of IKK with the human T-cell leukemia virus Tax protein. J Biol Chem.1999;274: 22911-22914.","DOI":"10.1074\/jbc.274.33.22911"},{"key":"2020021220134698900_","doi-asserted-by":"crossref","unstructured":"Jin DY, Giordano V, Kibler KV, Nakano H, Jeang KT. Role of adapter function in oncoprotein-mediated activation of NF-kappaB: human T-cell leukemia virus type I Tax interacts directly with IkappaB kinase gamma. J Biol Chem.1999;274: 17402-17405.","DOI":"10.1074\/jbc.274.25.17402"},{"key":"2020021220134698900_","doi-asserted-by":"crossref","unstructured":"Chu ZL, Shin YA, Yang JM, DiDonato JA, Ballard DW. IKKgamma mediates the interaction of cellular IkappaB kinases with the tax transforming protein of human T cell leukemia virus type 1. J Biol Chem.1999;274: 15297-15300.","DOI":"10.1074\/jbc.274.22.15297"},{"key":"2020021220134698900_REF37","doi-asserted-by":"crossref","unstructured":"Xiao G, Sun SC. Activation of IKKalpha and IKKbeta through their fusion with HTLV-I tax protein. Oncogene. 2000;19: 5198-5203.","DOI":"10.1038\/sj.onc.1203894"},{"key":"2020021220134698900_REF38","doi-asserted-by":"crossref","unstructured":"Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell. 1996;87: 13-20.","DOI":"10.1016\/S0092-8674(00)81318-5"},{"key":"2020021220134698900_REF39","doi-asserted-by":"crossref","unstructured":"Henkel T, Machleidt T, Alkalay I, Kronke M, Ben-Neriah Y, Baeuerle PA. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature. 1993;365: 182-185.","DOI":"10.1038\/365182a0"},{"key":"2020021220134698900_REF40","doi-asserted-by":"crossref","unstructured":"Beg AA, Finco TS, Nantermet PV, Baldwin AS Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol Cell Biol.1993;13: 3301-3310.","DOI":"10.1128\/MCB.13.6.3301"},{"key":"2020021220134698900_REF41","doi-asserted-by":"crossref","unstructured":"Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia. 2002;16: 433-443.","DOI":"10.1038\/sj.leu.2402417"},{"key":"2020021220134698900_","doi-asserted-by":"crossref","unstructured":"Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A. 1997;94: 855-860.","DOI":"10.1073\/pnas.94.3.855"},{"key":"2020021220134698900_REF43","doi-asserted-by":"crossref","unstructured":"Chandra J, Niemer I, Gilbreath J, et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood. 1998;92: 4220-4229.","DOI":"10.1182\/blood.V92.11.4220"},{"key":"2020021220134698900_REF44","doi-asserted-by":"crossref","unstructured":"Grossman WJ, Kimata JT, Wong FH, Zutter M, Ley TJ, Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci U S A. 1995;92: 1057-1061.","DOI":"10.1073\/pnas.92.4.1057"},{"key":"2020021220134698900_REF45","doi-asserted-by":"crossref","unstructured":"Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med.2002;8: S49-S54.","DOI":"10.1016\/S1471-4914(02)02315-8"},{"key":"2020021220134698900_REF46","unstructured":"Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res.1999;59: 2615-2622."},{"key":"2020021220134698900_REF47","unstructured":"Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res.2001;7: 1419-1428."},{"key":"2020021220134698900_","unstructured":"LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res.2002;62: 4996-5000."},{"key":"2020021220134698900_REF49","doi-asserted-by":"crossref","unstructured":"Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol.2002;6: 493-500.","DOI":"10.1016\/S1367-5931(02)00343-5"},{"key":"2020021220134698900_REF50","unstructured":"Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res.2002;62: 1083-1086."},{"key":"2020021220134698900_REF51","doi-asserted-by":"crossref","unstructured":"Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem.2002;277: 16639-16647.","DOI":"10.1074\/jbc.M200360200"},{"key":"2020021220134698900_REF52","doi-asserted-by":"crossref","unstructured":"Bours V, Bentires-Alj M, Hellin AC, et al. Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol.2000;60: 1085-1089.","DOI":"10.1016\/S0006-2952(00)00391-9"},{"key":"2020021220134698900_REF53","doi-asserted-by":"crossref","unstructured":"Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol.2001;159: 387-397.","DOI":"10.1016\/S0002-9440(10)61708-7"},{"key":"2020021220134698900_REF54","doi-asserted-by":"crossref","unstructured":"Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 1996;274: 784-787.","DOI":"10.1126\/science.274.5288.784"},{"key":"2020021220134698900_REF55","doi-asserted-by":"crossref","unstructured":"Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281: 1680-1683.","DOI":"10.1126\/science.281.5383.1680"},{"key":"2020021220134698900_REF56","doi-asserted-by":"crossref","unstructured":"Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs. 2000;18: 109-121.","DOI":"10.1023\/A:1006321828515"},{"key":"2020021220134698900_REF57","unstructured":"Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res.1996;56: 2649-2654."},{"key":"2020021220134698900_REF58","doi-asserted-by":"crossref","unstructured":"Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity. 1995;2: 493-506.","DOI":"10.1016\/1074-7613(95)90030-6"},{"key":"2020021220134698900_REF59","doi-asserted-by":"crossref","unstructured":"Schmitz ML, Bacher S, Kracht M. I kappa B-independent control of NF-kappa B activity by modulatory phosphorylations. Trends Biochem Sci.2001;26: 186-190.","DOI":"10.1016\/S0968-0004(00)01753-9"},{"key":"2020021220134698900_REF60","doi-asserted-by":"crossref","unstructured":"Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced antitumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med.1999;5: 412-417.","DOI":"10.1038\/7410"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/3\/802\/1700525\/zh801504000802.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/3\/802\/1700525\/zh801504000802.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T10:50:33Z","timestamp":1682679033000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/3\/802\/18502\/Effects-of-the-proteasome-inhibitor-PS341-on-tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,1]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-11-3967","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,1]]}}}